SF2000SD Clinical Trial in Zambia (SF2000SD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02941159|
Recruitment Status : Unknown
Verified November 2017 by Tropical Diseases Research Centre, Zambia.
Recruitment status was: Recruiting
First Posted : October 21, 2016
Last Update Posted : November 17, 2017
|First Submitted Date ICMJE||October 8, 2016|
|First Posted Date ICMJE||October 21, 2016|
|Last Update Posted Date||November 17, 2017|
|Study Start Date ICMJE||September 2016|
|Actual Primary Completion Date||November 2017 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT02941159 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||SF2000SD Clinical Trial in Zambia|
|Official Title ICMJE||A Phase I Single Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Safety and Tolerability of SF2000SD in Healthy Male Volunteers|
|Brief Summary||The purpose of this study is to assess the safety and tolerability of SF2000SD in adult male healthy volunteers|
INTRODUCTION: Treatment and management of people suffering from HIV, AIDS and opportunistic infections using conventional therapeutic interventions is beyond the reach of most governments because of the cost of imported medicines. The WHO has approved the strategy and promotion of the use of Traditional Medicine in Health Systems.
The primary health care places traditional medicines high on its list of priorities and emphasizes their easy availability and use. There is however a need for scientific validation of most potential medicinal plants available in many poor countries and research must focus on the safety and efficacy of these traditional medicines to support their widespread usage. This study intends to conduct a phase I clinical trial using the SF2000SD.
History of SF2000 use: The Sondashi Formula 2000, code named "SF2000" is a mixture of 4 plants. Patients suffering from HIV/AIDS have been using this traditional medicine for the management of their illness.
A more acceptable dosage form i.e. a spray dried extract (SF2000SD) has been developed based on the SF2000 inventor's traditional preparation the commencement of a phase I clinical safety study involving eligible adult male health individual volunteers is warranted. Information will be collected to scientifically ascertain the safety of SF2000 in these volunteers paving the way for a phase II clinical study to be conducted after phase I.
Study design: The study will be a longitudinal clinical trial of adult healthy male volunteers taking SF2000SD or placebo under directly observed therapy (DOT). The study participants will be randomized to each treatment arm as they are being enrolled into the study. Each treatment arm/group A, B and C will have fifteen (15) study participants, total 45. Apart from the PI the other investigators will be blinded to the participants' treatment arms. The study participants will also be blinded to the treatment arms and their contents.
Study site: The study shall be undertaken at the Tropical Diseases Research Centre, Ndola. Study personnel The following personnel will be available.
Recruitment: Sensitization and awareness posters, volunteer brochures and flyers, direct mailing and presentations will be given to the targeted community. Volunteers will receive further briefing from the Principal Investigator (PI) or Co-Principal Investigator. The briefing will be followed by an opportunity for questions from the volunteers. Potential study participants will be screened for eligibility to participate in the study. All study participants will receive counseling pertaining to their intent to participate in the study from qualified counselors of the research team. Written informed consent which will be validated by the PI or his designee will be obtained from all participants. Forty five (45) healthy males will be recruited into the study.
Method of assigning study participants to treatment arm/group: The blocked randomization method will be used to allocate the participants to the treatment. Selection of participants to each treatment will be based on the rank of 45 randomly generated numbers of sizes between 0 and 1, generated for each sequential participant. Accordingly, participants in blocks of 3 will be ranked according to the random number.
In each block the participants with the highest rank will be allocated to treatment A, the ones with the second highest will be allocated to treatment B, and the ones with the third highest will be allocated to treatment C. A randomization list with participants Identification (ID) numbers will be generated by the statistician and will be kept by the PI. Treatment packs will bear participant ID numbers. Only the PI will know the treatment allocations.
Drug administration: Participants will start taking the dose orally in their respective treatment arms when recruitment for the study is complete. In order to ensure that the study drug is taken, a Directly Observed Treatment (DOT) approach will be used. The study drug will be administered twice daily between 06.00hrs - 09.00hrs and 17.00hrs - 20.00hrs for six weeks. All administrations will be recorded on the dosing sheet and signed by the person administering the treatment and Co-PI or Medical Doctor.
Data Collection: The participants will be required to report any adverse events immediately. At each visit, the participants will also be interviewed on any adverse events since the previous visit. Furthermore, participants will be required to keep a dairy of adverse events for the duration of the study.
The laboratory tests will mainly be carried out at the Tropical Diseases Research Centre (Ndola), and Ndola Central Hospital (Ndola).
The frequency and data collection points at screening, baseline and weeks 1, 3, 6 and 8.
Screening: Week -2 to -1
Enrolment and study drug administration visit: Week 0
Data Entry: The data generated will be entered and analyzed by STATA computer software.
Statistical Analysis: Null Hypothesis set p-values The SF2000SD herbal preparation is not safe for human consumption P-value = 0.05.
The adverse events will be classified into three to five categories (Adverse events categories against the three "treatments"). Proportions will be compared using the Chi-square test. If the expected frequencies will be less than 5%, then the Fisher's t test will be used. The students' t test will be used to compare the means. The level of statistical significance will be set at 5%.
The clinical findings will also be classified into three to five categories and an exact chi-square test will be done.
If the null hypothesis (no association between occurrence of adverse events or physical examination findings for exact chi-square test and no difference in the changes for analysis of variance test) in the exact Chi-square test or the analysis of variance test is rejected then multiple comparison tests and stratified analysis will be done to compare the placebo against the other treatments.
Conduct interim analysis at week 3 of study starting from baseline (baseline to be all at the same time for all 45 participants if possible - must be included in randomization).
QUALITY CONTROL: The Investigators will review the consent and screening processes with all study stuff prior to commencement of the study to ensure that a standardized approach is followed during the study. In addition, the Investigators will frequently conduct performance assessments of the study support staff to ensure smooth collection of reliable data and review participants' concerns during the study. In addition the study monitor will visit at initiation, during the conduct of the study and at closure to verify if the study is being conducted in compliance with, Protocol/amendment(s), with Good Clinical Practices, Standard Operating Procedures (SOPs) and applicable regulatory requirements.
PROCEDURES TO HANDLE ADVERSE EVENTS: At admission for each treatment period study participants will be instructed to report any changes in normal health that they experience to the Principal Investigator or Co-Principal Investigator. AEs will also be elicited by indirect questioning at regular intervals, usually at the time of measurement of vital signs, with such questions as "How do you feel today? or "Is anything bothering you?" No study participant shall be permitted any medication during the study except as permitted by the study medical doctor.
All AEs or symptoms will be recorded in the CRF. Any SAE will be reported to the Principal Investigator/Co- Principal Investigator, within 48 hours (0977 655096 or 0966 263271), who in turn will report them to the Ethics Committee and DSMB. On the basis of the occurrence and severity of AEs, coupled with results of any other observations, the Principal Investigator or Co-Principal Investigator, at his discretion and in consultation with the DSMB, may decide to withdraw a study participant or prematurely end the study for reasons of clinical safety. The time of such termination will be recorded and palliative treatment will be instituted as needed.
TRIAL STOPPING RULES: The DSMB has the right to stop the trial based on the following rules:
REASONS FOR NOT COMPLETING THE STUDY: Participants may not complete the study for medical or non-medical reasons PROJECT MANGEMENT: The project will be managed by four investigators: PI, Co-PI (MD), Biostatistician and Social Scientist.
DATA MONITORING: Data Safety Monitoring Board (DSMB) will be responsible to monitor the progression of the study and analyzing the data generated.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Phase 1|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
|Condition ICMJE||Good Health|
|Study Arms ICMJE||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Unknown status|
|Estimated Enrollment ICMJE
|Original Actual Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||February 2018|
|Actual Primary Completion Date||November 2017 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
To be eligible to participate in study, the participant should be;
Anyone who meets ANY of the following exclusion criteria will NOT qualify for enrolment into the study.
|Ages ICMJE||18 Years to 45 Years (Adult)|
|Accepts Healthy Volunteers ICMJE||Yes|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Zambia|
|Removed Location Countries|
|NCT Number ICMJE||NCT02941159|
|Other Study ID Numbers ICMJE||SF2000SDPh1|
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement ICMJE||
|Responsible Party||Tropical Diseases Research Centre, Zambia|
|Study Sponsor ICMJE||Tropical Diseases Research Centre, Zambia|
|PRS Account||Tropical Diseases Research Centre, Zambia|
|Verification Date||November 2017|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP